The Icos Alumni: Where Are They Now?

11/18/09Follow @xconomy

(Page 9 of 9)

Liming Sui, pharmaceuticals professional

Tom Swallow, consultant

Jennifer Swank, analytical chemistry consultant, Swank Consulting

Janelle Taylor, senior research associate II, VLST

Elena Te, senior clinical design consultant, Phase Forward

Sally Teeters, director of legal and business operations management, Calistoga Pharmaceuticals

Bobbie Thomasson, senior research associate, Amgen

Eugene Thorsett, pharmaceutical consultant

James Tierney, accounting manager, Ste. Michelle Wine Estates

Karen Tindall, director of clinical data management, Innovative Analytics [Added 12/30/09]

Bill Tino, staff scientist, LigoCyte Pharmaceuticals

Larry Tjoelker, senior director of research, Xori

Carlos Toledano, vivarium manager, Benaroya Research Institute

Nate Toy, manufacturing associate III, Bio-Rad Laboratories

Sam Tran, senior associate scientist, Amgen

Carol Tranfaglia, manager of clinical data management, Cell Therapeutics [Added: 9:41 pm, 9/7/10]

Jennifer Treiberg, associate scientist II, Gilead Sciences

Stephanie Tuck, preclinical scientist, Uptake Medical

Brad Turcott, senior human resources manager, Seattle Genetics, director of human resources at Infospace

Terry Turner, director of business development, PSI

Stephanie Turner, biotechnology consultant

Nancy Upton, executive assistant to the president and CFO, Genie Industries

Linda Valentine, quality control analyst, ZymoGenetics

Mike Van Brunt, scientist, Allozyne

Mike Vandiver, director of pilot plant operations, Amgen

Marie Rose van Schravendijk, associate director of analytical and formulation development, CMC Icos

Rosemay Vazeux, scientist

Joachim Veith, senior drug safety scientist, Genentech/Roche [Added 12/30/09]

Satyanarayana Vunnam, scientist [Added 3/3/10]

Andy Walker, associate director manufacturing technical operations, CMC Icos

Susan Wang, strategic director for Asia, MDS Pharma Services

Margie Watson, ambassador of first impressions, CMC Icos

Steve Waugh, director of downstream process development, CMC Icos

Dave Weber, security engineer, Network Computing Architects

Joachim Weickmann, biotechnology professional

Joe Weil, senior scientist, Trubion Pharmaceuticals

Steven Whitaker, vice president of clinical development and chief medical officer, Allon Therapeutics

Claire White, administrative specialist, ZymoGenetics

Gary Wilcox, chairman and CEO, CoCrystal Discovery

Pamela Wilkendorf, senior CMC project manager, CMC Icos

Wendy Wisdom, senior associate scientist, Amgen

Sharon Wolda, senior program manager, Intellectual Ventures

Jeff Wood, associate director of global product development, PPD

Michele (Koethe) Yetman, vice president of human resources, technology, Amazon.com

Albert Yu, vice president, clinical affairs, chief medical officer, Calistoga Pharmaceuticals

Patricia Zajac, executive coordinator, Gilead Sciences

Kristin Ziegler, process development manager, CMC Icos

Single Page Currently on Page: 1 2 3 4 5 6 7 8 9 previous page

By posting a comment, you agree to our terms and conditions.

  • http://www.northcoastbio.com Johnny T. Stine

    I actually loved our logo – very simple, but it just looked like fun.
    When George R. was recently asked by a reporter from an Everett newspaper about building Icos into a company like Amgen….he replied “…..why would I stop there?”. With a leader like that, like George, one who inspires with energetic goals such as that mentioned – we could’ve done it. We had the tools and the ability to do just that. We had great people who’ve all proven themselves in places before and afterward…….but imagine what we could’ve done behind the hopes of a great leader like George who set that tone….a CEO who knew all of our names, someone who would talk to you like you were a valued asset, a guy that empowered us via ownership. Imagine what we could’ve done…..because that’s all we’re left to do.

    By the way- Luke – I prefer Icosanoids – a play on the word eicosanoid since we were primarily an inflammation company. :-)

  • http://www.xconomy.com/author/ltimmerman/ Luke Timmerman

    Johnny—Unfortunately, I never really got to know George very well because he had already left Icos by the time I started covering the company in 2001. But I made a point of meeting him at his home once a couple years ago when I was based in San Francisco. He wasn’t in great health, but he was still sharp and very much curious about the latest happenings in biotech.

    I haven’t heard the term Icosanoids from eicosanoid, but that made me laugh this morning. It sounds like something from Star Trek. Anybody know if this was also the inspiration for the term “Immunoids” for people who used to work at Immunex?

  • http://www.BiotechStockResearch.com David Miller

    Nice work, Luke. Goes to prove that even though we might lose companies through acquisition we’d really rather keep, it’s not like everything connected with the company disappears. By my eye, the “loss” of Icos created at least a half-dozen new companies and significantly strengthened a dozen or more startups. A nice silver lining.

  • Abby Kliphardt

    Nice article…good to see where my co-workers have ended. I loved my time at ICOS and will always lament the loss of a great company that was a real family….

  • Pingback: The Icos Impact: What to Expect Next Week | Xconomy